Intrinsiq Materials is leading a consortium to develop its novel nanoparticle copper ink technology for use in medical devices under the UK Government funded PROCID programme
The PROCID program will run to the end of 2013 and is designed to prove the cost effective use of printed copper in low cost antibody based biosensors for disease detection, initially targeting the STD’s Chlamydia and Gonorrhea.
The consortium consists of distinguished specialist partners – Leeds University, ELISHA Systems Ltd, The Ryedale Group, The Needham Group, Amies Innovations and P1 Technology, with Intrinsiq Materials leading the programme and providing their novel copper ink technology.
Intrinsiq Materials is an advanced materials company with facilities in Farnborough UK and Rochester, NY, providing nanoparticle-based copper ink formulations for printed electronics applications. Intrinsiq’s copper inkjet ink, Intrinsiq CI', and copper screen print paste, Intrinsiq CP, are innovative ink formulations designed for photonic curing at room temperature in air, by laser or broad band flash techniques. Conductivities are comparable to commercial silver inks on a range of substrates, including PET and paper. The company has additional inks under development, including nanoparticle-based nickel and silicon.
“Several key potential endusers are assessing our inks in a range of applications including security, displays and PV,” said Ian Clark, sales and marketing director. “The potential in medical device applications is an exciting development which will be accelerated by the PROCID program.”